Enzymatica AB Share Price

Equities

ENZY

SE0003943620

Pharmaceuticals

Delayed Nasdaq Stockholm 14:30:33 29/04/2024 BST 5-day change 1st Jan Change
2.87 SEK -6.82% Intraday chart for Enzymatica AB -16.81% -27.25%

Financials

Sales 2024 * 6.04M 66.02M 482M Sales 2025 * 11.85M 129M 946M Capitalization 48.71M 532M 3.89B
Net income 2024 * -5M -54.63M -399M Net income 2025 * -1M -10.93M -79.84M EV / Sales 2024 * 8.59 x
Net Debt 2024 * 3.18M 34.78M 254M Net cash position 2025 * 2.05M 22.42M 164M EV / Sales 2025 * 3.94 x
P/E ratio 2024 *
-16.5 x
P/E ratio 2025 *
-35.1 x
Employees 18
Yield 2024 *
-
Yield 2025 *
-
Free-Float 34.79%
More Fundamentals * Assessed data
Dynamic Chart
1 day-6.82%
1 week-16.81%
Current month-11.69%
1 month-12.50%
3 months-18.23%
6 months-23.36%
Current year-27.25%
More quotes
1 week
2.81
Extreme 2.81
3.59
1 month
2.81
Extreme 2.81
3.94
Current year
2.31
Extreme 2.305
4.10
1 year
2.10
Extreme 2.1
4.43
3 years
2.10
Extreme 2.1
13.40
5 years
1.88
Extreme 1.88
24.70
10 years
1.82
Extreme 1.815
24.70
More quotes
Managers TitleAgeSince
Founder 59 31/12/06
Chief Executive Officer 63 17/07/17
Director of Finance/CFO 55 31/12/17
Members of the board TitleAgeSince
Chairman 62 18/12/16
Director/Board Member 56 14/02/16
Director/Board Member 57 30/04/21
More insiders
Date Price Change Volume
29/04/24 2.87 -6.82% 142 860
26/04/24 3.08 -4.94% 173,251
25/04/24 3.24 -8.22% 96,511
24/04/24 3.53 +2.62% 12,555
23/04/24 3.44 -0.29% 23,983

Delayed Quote Nasdaq Stockholm, April 29, 2024 at 02:30 pm

More quotes
Enzymatica publ AB is a Sweden-based company engaged in biotechnology. It researches, develops and registers enzyme-based health and wellbeing products. The Company uses a patented enzyme, Penzyme, a cold-adapted trypsin from deep sea cod. The enzyme is active at about 37 Celsius degree and decomposes disease-related proteins, counteracting viral and bacterial infections and supporting healing processes. The Company conducts clinical studies of ColdZyme Munspray, a cold medicine. It operates such subsidiaries, as Enzymatica Care AB, Zymetech ehf, among others. Main shareholders of Enzymatica AB are Humea AB, Medi AB, and Nordic Consulting Group AB, among others. In November 2013, the Company established another subsidiary in the United States, Enzymatica North America Inc., responsible for future production and sale of veterinary products in the United States and Canada.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

Quarterly revenue - Rate of surprise